A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects

NCT02802514 on ClinicalTrials.gov · last registry update 2020-10-30

Stopped early, having planned 5 participants. The sponsor logged completion for 10 August 2017. Primary outcome, as filed: Blood Oxygen Level Dependent (BOLD) Signal by Functional Magnetic Resonance Imaging (fMRI) Visual Nauseogenic Task. exenatide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: TERMINATED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: GlaxoSmithKline
Sponsor type: Industry
Enrollment: 5
Started: 2016-09-20
Primary completion: 2017-08-10 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Blood Oxygen Level Dependent (BOLD) Signal by Functional Magnetic Resonance Imaging (fMRI) Visual Nauseogenic Task

Conditions studied

Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.